NSE · WALPAR · Pharmaceuticals
Walpar Nutritions Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹72 Cr with net profit ₹2 Cr — a 3.23% net margin, versus 2.52% the period before.
Shareholding
As of 2026-03-31
- Promoter68.82%
- Public31.18%
327 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.38× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ST-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,80,107 Cr | 38.63 | 5.74 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,18,487 Cr | 213.49 | 3.44 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,162 Cr | 20.46 | 4.1 | 18.59% | 18.86% |
| Lupin Limited | ₹1,10,682 Cr | 19.46 | 4.93 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,06,194 Cr | 52.71 | 6.51 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,305 Cr | 88.06 | 18.17 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,611 Cr | 432.26 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹91,645 Cr | 99.49 | 2.42 | 9.25% | 10.5% |
| Alkem Laboratories Ltd. | ₹69,503 Cr | 294.03 | 5.03 | 16.66% | 15.65% |
| Biocon Ltd. | ₹69,034 Cr | 539.11 | 2.03 | 1.14% | 2.3% |
| Walpar Nutritions Limited(this company) | — | 16.67 | 1.93 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashWalpar Nutritions Limited, operating in the Pharmaceuticals sector, has a market capitalization of Rs 105 Cr. The company's PE ratio is 16.67, with an EPS of 2.09. The book value stands at 18.08, and the ROCE for the company is 17.64%. The debt-to-equity ratio is 0.53.
Positives
- +Revenue grew from Rs 6.0723 Cr in Mar 2021 to Rs 72.0292 Cr in Mar 2025.
- +The debt-to-equity ratio is 0.53.
- +Promoter shareholding is 68.8189% as of March 31, 2026, with 0% pledged shares.
Negatives
- −The company's Return on Equity (ROE) is not available.
- −The profit margin for the company is not available.
- −Promoter holding decreased from 71.4603% in May 2023 to 68.8189% in March 2026.
- −The company is under ST-ASM (Additional Surveillance Measure) Stage 1.
Financial performance
The company reported revenue growth of 14.78%. Revenue increased from Rs 6.0723 Cr in Mar 2021 to Rs 72.0292 Cr in Mar 2025. Net profit also rose from Rs 0.1502 Cr in Mar 2021 to Rs 2.3244 Cr in Mar 2025. EPS grew from 0.46 in Mar 2021 to 2.48 in Mar 2025.
Profitability & returns
Walpar Nutritions Limited's ROCE is 17.64%. The EPS has shown growth, increasing from 0.46 in Mar 2021 to 2.48 in Mar 2025. There is no information available for Return on Equity (ROE) or profit margin.
Balance sheet
The company maintains a debt-to-equity ratio of 0.53, indicating its reliance on debt for financing. The book value per share is 18.08. No dividend pay-out is reported for the company as dividend yield is null.
Ownership & pledges
Public shareholding is 31.1811%. There is no promoter share pledge reported. The number of shareholders is 327 as of March 31, 2026.
Regulatory & surveillance
Walpar Nutritions Limited is currently under ST-ASM (Additional Surveillance Measure) Stage 1. This indicates that the stock has been flagged for certain surveillance actions by regulatory bodies.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.